5 years ago

Serum sclerostin levels in adults with osteogenesis imperfecta: comparison with normal individuals and response to teriparatide therapy

Eric Orwoll, Sandesh C.S. Nagamani, Ying Wang, John Sloan, Brendan Lee, Rosamund Smith, Lindsey Nicol, Jay Shapiro
Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta [1] is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared to age- and sex- matched control participants, mean SOST levels were lower in those with Type I or Types III/VI OI (P < 0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87 respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared to placebo, P = 0.01). The increase was significant at 6, 12, and 24 months of therapy (P < 0.02), and was apparent as early as 3 months (P = 0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral vBMD. Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta, 2) serum SOST levels could be a biomarker of OI in adults, and 3) and alterations in SOST may help predict the response to anabolic therapies in OI. This article is protected by copyright. All rights reserved

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/jbmr.3312

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.